Following the results from the Phase Ib Keynote012 study (21) and from the phase II Keynote-059 cohort 1 (22), the U.S. Food and Drug Administration (FDA) has approved pembrolizumab for third-line treatment of PD-L1+ [combined positive score (CPS) ≥ 1%] recurrent or metastatic GC/GEJC adenocarcinoma (22–25). Here, CD274 is linked to gastric cancer.